The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India

Table 1

Emetogenic Potential of Chemotherapeutic Agents.

Level	Agent
High emetic risk (>90% frequency of emesis)	(i) AC combination defined as either doxorubicin or epirubicin with cyclophosphamide; (ii) Carmustine >250 mg/m^2; (iii) Cisplatin ≥50 mg/m^2; (iv) Cyclophosphamide >1500 mg/m^2; (v) Dacarbazine; (vi) Doxorubicin > 60 mg/m^2; (vii) Epirubicin >90 mg/m^2; (viii) Ifosfamide ≥ 10 g/m^2; (ix) Mechlorethamine; (x) Streptozocin
Moderate emetic risk (30%–90% frequency of emesis)	(i) Aldesleukin > 12–15 million international units/m^2; (ii) Amifostine > 300 mg/m^2; (iii) Arsenic trioxide; (iv) Azacitidine; (v) Bendamustine; (vi) Busulfan; (vii) Carboplatin; (viii) Carmustine ≤ 250 mg/m^2; (ix) Cisplatin < 50 mg/m^2; (x) Clofarabine; (xi) Cyclophosphamide ≤ 1500 mg/m^2; (xii) Cytarabine >200 mg/m^2; (xiii) Dactinomycin; (xiv) Daunorubicin; (xv) Doxorubicin ≤ 60 mg/m^2; (xvi) Epirubicin ≤ 90 mg/m^2; (xvii) Idarubicin; (xviii) Ifosfamide < 10 g/m^2; (xix) Interferon alfa ≥ 10 million international units/m^2; (xx) Irinotecan; (xxi) Melphalan; (xxii) Methotrexate ≥ 250 mg/m^2; (xxiii) Oxaliplatin; (xxiv) Temozolomide